Is BMJ Open a Good Journal? An Honest Assessment

BMJ Open publishes research that answers clear questions with appropriate methods. No novelty requirement. No "clinical significance" filter. No preference for positive results.

The journal accepts clinical trials, observational studies, systematic reviews, and study protocols. It also publishes negative results, which most selective journals won't touch. This makes it particularly valuable for researchers conducting pre-registered studies or replication attempts.

What does get desk-rejected? Case reports with fewer than three cases. Basic science without clear clinical relevance. Studies that don't follow established reporting guidelines (CONSORT, STROBE, PRISMA). Manuscripts where the research question isn't clearly stated in the first paragraph. According to BMJ Publishing Group data, desk rejection accounts for a significant share of decisions, mostly on these grounds.

The scope covers anything that fits under "medical research": clinical trials, epidemiological studies, health services research, public health interventions, health economics analyses. If you can make a reasonable argument that it matters for human health, BMJ Open will consider it.

One thing that separates BMJ Open from purely volume-driven journals: they actually enforce methodological standards. Underpowered studies get rejected. Studies with obvious confounding that isn't addressed get rejected. Analyses that don't match the stated objectives get rejected.

BMJ Open uses completely transparent peer review. When your paper gets accepted, the reviewer comments get published alongside the article. Reviewer names are included unless they specifically request anonymity.

This changes the review dynamics in documented ways. Per research on open peer review outcomes, reviewers tend to be more constructive and less adversarial when their comments are public. Authors get more detailed, actionable feedback. Readers can evaluate the peer review quality for themselves.

But it also means your study gets more scrutiny, not less. Other researchers can see exactly what concerns the reviewers raised and how you addressed them. If your methods are questionable, that becomes part of the permanent record.

The practical impact: if you're confident in your methods and comfortable with transparency, BMJ Open's open peer review is an advantage. If your study has significant limitations or your methods are borderline, the published review record is something to consider.

One unexpected benefit: we see cases where published reviewer comments actually increase the paper's credibility because readers can verify that methodological concerns were raised and addressed. For clinical researchers building a track record of rigorous work, this transparency is an asset.

SciRev community data shows mixed experiences. Some authors report efficient processes with decisions in under 3 months. Others report reviewer selection alone taking 2+ months. The median of approximately 134 days (19 weeks) to first decision is consistent with a thorough but not fast journal.

Common desk-rejection reasons are straightforward: the manuscript doesn't really fit human-health research, the reporting is incomplete, the question is unclear, or the design doesn't support the claims being made.

In our pre-submission review work with manuscripts targeting BMJ Open, we see three patterns that consistently derail otherwise publishable papers.

The reporting checklist that's technically present but substantively incomplete. This sinks more BMJ Open submissions than weak study design. We find that roughly 40% of the clinical manuscripts we review have a CONSORT or STROBE checklist that's been filled in, but the actual manuscript doesn't match the checklist entries. The checklist says "see Methods" for half the items, but the Methods section doesn't actually contain the required information. BMJ Open editors catch this, and it's an automatic desk rejection. In practice, the 30 minutes it takes to properly align your reporting checklist with your manuscript text is the highest-return pre-submission investment for this journal.

The framing hangover from a higher-tier rejection. We notice this in roughly 30% of manuscripts targeting BMJ Open after rejection from The BMJ or a specialty journal. The introduction still reads like it's selling clinical significance: "this study will transform clinical practice" or "our findings have immediate implications for patient care." BMJ Open editors respond better to honest, proportionate framing. The paper was rejected from a significance-filtered journal for lacking significance. Don't keep selling significance to a journal that doesn't filter for it.

The underpowered study disguised by post-hoc analysis. According to editorial data, BMJ Open rejects a notable share of quantitative manuscripts where the primary analysis was clearly underpowered but the authors added multiple post-hoc subgroup analyses to find something publishable. Soundness-based review doesn't mean statistical fishing is acceptable. BMJ Open reviewers flag this, and because the review is published openly, the statistical concerns become part of the public record even if the paper is eventually accepted after revision.

Before submitting, a BMJ Open reporting check catches exactly the reporting gaps, framing mismatches, and statistical issues that account for most BMJ Open desk rejections.

Strengths:

• BMJ brand recognition carries weight with promotion committees and grant reviewers
• Open peer review provides transparent accountability
• Strong home for protocols, negative results, and implementation science
• PubMed, Web of Science, and Scopus indexing
• Consistent enforcement of reporting guidelines (CONSORT, STROBE, PRISMA)

Limitations:

• SciRev data shows review times can stretch significantly, with some authors reporting 34+ weeks to first decision
• The IF (2.3) is low relative to the APC (~$3,250); cost-per-citation is high
• Open peer review means methodological critiques become permanently visible
• The journal's high publication volume (~4,900 articles/year) means individual papers get less editorial attention than at more selective venues